ClinicalTrials.gg
CompletedNCT01024920Updated Jul 19, 2021Results posted

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

A Phase 2 interventional study of BIBF 1120 and sunitinib in Carcinoma, Renal Cell, sponsored by Boehringer Ingelheim. Completed at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-19.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Carcinoma, Renal Cell with a site in Ukraine — none open to participants now, 6 under way, 5 of them phase 3. Carcinoma, Renal Cell · Ukraine.

Enrollment
19th of 22
99 · median 275
Started
2009
with 1 other
Phase 2
5 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
1 of 22
Boehringer Ingelheim

Among the 22 studies in Carcinoma, Renal Cell with a site in Ukraine, this one is the 19th largest by enrollment, is one of 2 that started in 2009, is one of 5 in phase 2, and was the 10th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

None of the 22 studies in Carcinoma, Renal Cell with a site in Ukraine is open now. The open studies under Carcinoma, Renal Cell, anywhere →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Carcinoma, Renal Cell with a site in Ukraine as a file.
02

Study summary

Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).

03

Conditions studied

  • Carcinoma, Renal Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with unresectable or Renal Cell Cancer, who have received no previous systemic anti-cancer treatment.
  2. Histological-confirmed diagnosis of renal cell cancer with clear cell component.
  3. Acceptable renal,liver,cardiovascular,bone marrow and other functions to allow sunitinib/BIBF 1120 treatment.

Exclusion criteria

Exclusion criteria:

  1. Patients unable to tolerate Sunitinib/BIBF 1120 treatment
  2. Treatment with other drugs or participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study.
  3. Patients unable to comply with the 1199.26 protocol.
  4. Pregnancy or breast feeding.
  5. Active alcohol or drug abuse.
  6. Women of child bearing potential, or men who are able to father a child, unwilling to use a medically acceptable form of during the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Nintedanib (BIBF 1120)

    Non-marketed substance: Twice daily oral doses of 200mg BIBF 1120 given continuously.

    Drug: BIBF 1120

  • Active comparator
    sunitinib

    Marketed substance: Once a day oral doses of 50mg sunitinib given in repeated 6 week cycles: 4 weeks active, 2 weeks rest.

    Drug: sunitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Probability Rates of Progression-free Survival at 9 Months

    Progression free survival rate at 9 months is the estimated probability of being alive and not having progressive disease at 9 months after randomisation. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria version 1.1 (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.

    Time frame: At 9 months after randomisation.

  2. Time-matched Change From Baseline to Day 15 in QTcF (QT Interval Corrected by the Fridericia Formula) at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

    QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QTcF measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h,1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of are reported.

    Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Secondary outcomes

  1. Progression Free Survival (PFS)

    Progression free survival (PFS) from randomisation to the occurrence of disease progression (by RECIST Version 1.1) or death, whichever occurred first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.

    Time frame: From the start of study until the cut-off date for 3 year efficacy analysis, up to 3 years.

  2. Objective Response According to RECIST Criteria

    Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1. Numbers of participants with objective response are reported. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.

    Time frame: From the start of study until the cut-off date for 3 year efficacy analysis, up to 3 years.

  3. Duration of Objective Response

    Duration (months) of objective response was measured from the time of first objective response to the time of disease progression (by RECIST Version 1.1) or death, whichever occurred first. Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.

    Time frame: From the time of first objective response to the time of disease progression or death (whichever comes first), up to 3 years.

  4. Overall Survival

    Overall survival was calculated as the time (months) from randomisation to death. Patients for whom there was no evidence of death at the time of analysis were censored on the date that they were last known to have been alive. The Kaplan-Meier method was used to calculate the estimates.

    Time frame: From randomisation to death, up to 3 years.

  5. Time to Progression

    Time to progression is defined as the time period from randomisation to objective tumour progression. Patients with no progression (by RECIST Version 1.1) were censored at the date of the last evaluable imaging. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.

    Time frame: From randomisation up to objective tumour progression, up to 3 years.

  6. Time to Treatment Failure

    Time to treatment failure was defined as the time from randomisation to objective tumour progression (by RECIST Version 1.1), death, global deterioration of health status requiring treatment discontinuation, or start of new anticancer treatment, whichever came first. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.The Kaplan-Meier method was used to calculate the estimates.

    Time frame: From randomisation up to objective tumour progression, up to 3 years.

  7. Time-matched Change From Baseline to Day 1 in QTcF (QT Interval Corrected by the Fridericia Formula) at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

    QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QTcF measurement at time t. Time-matched change from baseline to Day 1 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported.

    Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 of treatment Cycle 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

  8. Time-matched Change From Baseline in QTcF Interval (QT Interval Corrected by the Fridericia Formula) at the Time of Each Participant's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  9. Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  10. Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  11. Average Time-matched Changes From Baseline in QTcF Interval Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1

    Average time-matched in QTcF interval (QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula) changes over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

    Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

  12. Time-matched Changes From Baseline to Day 15 in QT Interval at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

    QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QT measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of Cycle 1are reported.

    Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

  13. Time-matched Changes From Baseline to Day 1 in QT Interval at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

    QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QT measurement at time t. Time-matched change from baseline to Day 1 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported.

    Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

  14. Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  15. Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

  16. Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  17. Averaged Time-matched Changes From Baseline in QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1

    Averaged time-matched QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

    Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle.

  18. Time-Matched Heart Rate (HR) Changes From Baseline to Day 15 at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

    Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 15 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 15 obtained at time t minus baseline HR measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 15 of Cycle 1 are reported.

    Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

  19. Time-Matched Heart Rate (HR) Changes From Baseline to Day 1 at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

    Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 1 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 1 obtained at time t minus baseline HR measurement at time t. Time-matched change from baseline to Day 1 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 1 are reported.

    Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

  20. Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Nintedanib (BIBF 1120) Plasma Concentration, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  21. Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  22. Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of treatment cycle 1. Continues in the description.

  23. Averaged Time-Matched Heart Rate (HR) Change From Baseline Over 1 to 12 Hours, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    Averaged time-matched heart rate changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

    Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15.

  24. Frequency of Patients With Maximum Time-Matched QTcF Interval Change From Baseline Categorized by Magnitude of Change, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of patients with maximum time-matched change from baseline in the QTcF interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined: \<= 30 milliseconds (ms) \> 30 to 60 milliseconds (ms) \> 60 milliseconds (ms) Changes more than 60 ms in the QTcF interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  25. Frequency of Patients With Maximum Time-Matched QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Change From Baseline Categorized by Magnitude of Change, Days 1 and 15

    Number of patients with maximum time-matched change from baseline in the QT interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined: \<= 30 milliseconds (ms) \> 30 to 60 milliseconds (ms) \> 60 milliseconds (ms) Changes more than 60 ms in the QT interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  26. Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF ≤450 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset (not present at any time pre-dose) of QTcF ≤450 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  27. Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF >450 to 470 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF \>450 to 470 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

  28. Number of Participants With New Onset of QTcF> 470 to 500 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF\> 470 to 500 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

  29. Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF> 500 Milliseconds (ms) (Notable Prolongation), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF\> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

  30. Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QT (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) > 500 ms (Notable Prolongation), Days 1 and 15 of Treatment Cycle 1

    Number of participants with new onset of QT (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave)\> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

  31. Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in PR Interval

    The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib) and at Day 1 (first drug dose of nintedanib (BIBF 1120)) and changes from baseline to Day 1 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported.

    Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

  32. Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in PR Interval

    The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib (BIBF 1120) and at Day 15 (steady state) and changes from baseline to Day 15 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported.

    Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

  33. Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in QRS Interval

    QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 1 (first drug dose of nintedanib (BIBF 1120)) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported.

    Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

  34. Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in QRS Interval

    QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 15 (steady state) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported.

    Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

  35. Frequency of Patients by Clinical Electrocardiogram (ECG) Measurement Interpretation, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

    Based on the interpretation of the electrocardiogram (ECG) patients were classified in 3 categories: * Normal (a normal ECG reading would be a reading that includes the following normal findings: 1) normal general features; 2) no arrhythmia; 3) no conduction delays; 4) T-wave morphology of normal; and 5) normal U-wave morphology) on Day 1 or on Day 15) * Not normal and not normal at baseline (an abnormal ECG reading would be a reading that includes one or more of the following abnormal findings: 1) abnormal general features; 2) arrhythmia; 3) conduction delays; 4) T-wave morphology of flat, inverted or biphasic; and 5) abnormal U-wave morphology) on Day 1 or on Day 15) * Not normal and new onset of finding; Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

    Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

  36. Frequency of Adverse Events Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0

    The number of participants who experienced adverse events graded according to NCI CTCAE version 3.0, is reported below.The maximum grade of adverse event intensity for each type of treatment-related adverse event was recorded for each patient. Grade 1 - Mild AE Grade 2 - Moderate AE Grade 3 - Severe AE Grade 4 - Life-threatening or disabling AE Grade 5 - Death related to AE

    Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

  37. Number of Participants With Adverse Events Leading to Dose Reduction

    Number of participants who experienced Adverse Events which led to dose reduction of the trial medication is reported for each treatment arm.

    Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

  38. Number of Participants With Adverse Events Leading to Discontinuation of Trial Drug

    Number of participants with Adverse Events which lead to discontinuation of trial medication drug is reported for each treatment arm.

    Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

  39. Number of Participants With Adverse Events Requiring or Prolonging Hospitalisation

    Number of participants who experienced Adverse Events which required or prolonged hospitalisation of patients is reported for each treatment arm.

    Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

  40. Duration of Hospital Stays Due to Adverse Events Requiring or Prolonging Hospitalisation

    Duration of hospitalisation in days for each treatment arm is reported for those patients who experienced adverse events which required or prolonged hospitalisation (of the patients).

    Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

  41. Frequency of Patients With Possible Clinically Significant Abnormal Lab Values

    Number of patients with possible clinically significant abnormal lab values for the lab parameters alkaline phosphatase, activated partial thromboplastin time (APTT), creatinine, haemoglobin, prothrombin time (PT)-international normalized ratio (INR), potassium, lymphocytes, sodium, neutrophils, platelets, aspartate amino transferase (AST), alanine aminotransferase (ALT), bilirubin and white blood cell count is reported. Only lab values with CTCAE rule for possible clinical significance are displayed.

    Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

07

Results

Posted Jun 17, 2020

Participant flow

An open-label, 2:1 randomised, parallel-arm comparison of nintedanib versus sunitinib in patients with advanced renal cell cancer (RCC) who had not received prior systemic therapy.

Participant flow — Overall Study
MilestoneNintedanib (BIBF 1120)Sunitinib
Started6732
Treated6432
Completed00
Not completed6732
Withdrew: Progressive disease4725
Withdrew: Adverse event84
Withdrew: Lost to follow-up01
Withdrew: Patient refusal to continue40
Withdrew: Other than listed51
Withdrew: Not treated30
Withdrew: Protocol violation01

Outcome measures

PrimaryProbability Rates of Progression-free Survival at 9 Months

Progression free survival rate at 9 months is the estimated probability of being alive and not having progressive disease at 9 months after randomisation. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria version 1.1 (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.

Time frame:
At 9 months after randomisation.
Reported as:
Number · Probability
Probability Rates of Progression-free Survival at 9 Months
ProbabilityNintedanib (BIBF 1120)Sunitinib
Probability Rates of Progression-free Survival at 9 Months0.431 (0.306 to 0.550)0.452 (0.274 to 0.614)
Statistical analysis
  • Nintedanib (BIBF 1120) vs Sunitinib · Normal approximation test · p = 0.8531 (P-value for comparison of Kaplan-Meier estimates at 9 months using normal approximation test (two-sided).)
PrimaryTime-matched Change From Baseline to Day 15 in QTcF (QT Interval Corrected by the Fridericia Formula) at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QTcF measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h,1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of are reported.

Time frame:
At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Reported as:
Least squares mean · milliseconds (ms)
Time-matched Change From Baseline to Day 15 in QTcF (QT Interval Corrected by the Fridericia Formula) at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
milliseconds (ms)Nintedanib (BIBF 1120)
Time-matched change from baseline to Day 15 at -5 minutes (min)2.6 (-0.7 to 5.9)
Time-matched change from baseline to Day 15 at 1 hour (h)0.4 (-2.8 to 3.7)
Time-matched change from baseline to Day 15 at 2 h-1.7 (-4.9 to 1.6)
Time-matched change from baseline to Day 15 at 3 h-0.5 (-3.8 to 2.8)
Time-matched change from baseline to Day 15 at 4 h-0.5 (-3.8 to 2.8)
Time-matched change from baseline to Day 15 at 5 h0.3 (-3.0 to 3.6)
Time-matched change from baseline to Day 15 at 6 h2.2 (-1.1 to 5.5)
Time-matched change from baseline to Day 15 at 7 h3.1 (-0.2 to 6.4)
Time-matched change from baseline to Day 15 at 10 h0.1 (-3.2 to 3.4)
Time-matched change from baseline to Day 15 at 12 h1.6 (-1.7 to 4.9)
SecondaryProgression Free Survival (PFS)

Progression free survival (PFS) from randomisation to the occurrence of disease progression (by RECIST Version 1.1) or death, whichever occurred first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.

Time frame:
From the start of study until the cut-off date for 3 year efficacy analysis, up to 3 years.
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsNintedanib (BIBF 1120)Sunitinib
Progression Free Survival (PFS)8.44 (5.59 to 11.10)8.38 (5.59 to 13.86)
Statistical analysis
  • Nintedanib (BIBF 1120) vs Sunitinib · Log Rank · p = 0.6395 · Hazard ratio (hr): 1.120 · 95% CI 0.697 to 1.800Hazard ratio from Cox proportional hazards model stratified by Motzer risk score and previous surgery.
SecondaryObjective Response According to RECIST Criteria

Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1. Numbers of participants with objective response are reported. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.

Time frame:
From the start of study until the cut-off date for 3 year efficacy analysis, up to 3 years.
Reported as:
Count of participants · Participants
Objective Response According to RECIST Criteria
ParticipantsNintedanib (BIBF 1120)Sunitinib
Complete Response01
Partial response1411
Statistical analysis
  • Nintedanib (BIBF 1120) vs Sunitinib · Regression, Logistic · p = 0.1213 · Odds ratio (or): 0.484 · 95% CI 0.193 to 1.212Odds ratio \> 1 favours nintedanib.
SecondaryDuration of Objective Response

Duration (months) of objective response was measured from the time of first objective response to the time of disease progression (by RECIST Version 1.1) or death, whichever occurred first. Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.

Time frame:
From the time of first objective response to the time of disease progression or death (whichever comes first), up to 3 years.
Reported as:
Median · Months
Duration of Objective Response
MonthsNintedanib (BIBF 1120)Sunitinib
Duration of Objective Response19.42 (8.31 to NA)11.66 (7.06 to 28.45)
SecondaryOverall Survival

Overall survival was calculated as the time (months) from randomisation to death. Patients for whom there was no evidence of death at the time of analysis were censored on the date that they were last known to have been alive. The Kaplan-Meier method was used to calculate the estimates.

Time frame:
From randomisation to death, up to 3 years.
Reported as:
Median · Months
Overall Survival
MonthsNintedanib (BIBF 1120)Sunitinib
Overall Survival20.37 (13.86 to 29.01)21.22 (11.01 to 31.74)
Statistical analysis
  • Nintedanib (BIBF 1120) vs Sunitinib · Log Rank · p = 0.7593 (P-value from log-rank stratified by Motzer risk score and previous surgery.) · Hazard ratio (hr): 0.920 · 95% CI 0.542 to 1.564Hazard ratio from Cox proportional hazards model stratified by Motzer risk score and previous surgery. Hazard ratio \< 1 favours nintedanib.
SecondaryTime to Progression

Time to progression is defined as the time period from randomisation to objective tumour progression. Patients with no progression (by RECIST Version 1.1) were censored at the date of the last evaluable imaging. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.

Time frame:
From randomisation up to objective tumour progression, up to 3 years.
Reported as:
Median · Months
Time to Progression
MonthsNintedanib (BIBF 1120)Sunitinib
Time to Progression8.48 (7.56 to 11.20)8.54 (5.68 to 13.90)
Statistical analysis
  • Nintedanib (BIBF 1120) vs Sunitinib · Log Rank · p = 0.5958 · Cox proportional hazard: 1.143 · 95% CI 0.697 to 1.873Hazard ratio from Cox proportional hazards model stratified by Motzer risk score and previous surgery. Hazard ratio \< 1 favours nintedanib.
SecondaryTime to Treatment Failure

Time to treatment failure was defined as the time from randomisation to objective tumour progression (by RECIST Version 1.1), death, global deterioration of health status requiring treatment discontinuation, or start of new anticancer treatment, whichever came first. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.The Kaplan-Meier method was used to calculate the estimates.

Time frame:
From randomisation up to objective tumour progression, up to 3 years.
Reported as:
Median · Month
Time to Treatment Failure
MonthNintedanib (BIBF 1120)Sunitinib
Time to Treatment Failure8.44 (5.62 to 10.97)8.36 (5.55 to 13.86)
Statistical analysis
  • Nintedanib (BIBF 1120) vs Sunitinib · Log Rank · p = 0.5712 · Hazard ratio (hr): 1.142 · 95% CI 0.720 to 1.812Hazard ratio from Cox proportional hazards model stratified by Motzer risk score and previous surgery. Hazard ratio \< 1 favours nintedanib.
SecondaryTime-matched Change From Baseline to Day 1 in QTcF (QT Interval Corrected by the Fridericia Formula) at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QTcF measurement at time t. Time-matched change from baseline to Day 1 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported.

Time frame:
At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 of treatment Cycle 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Reported as:
Least squares mean · milliseconds (ms)
Time-matched Change From Baseline to Day 1 in QTcF (QT Interval Corrected by the Fridericia Formula) at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
milliseconds (ms)Nintedanib (BIBF 1120)
Time-matched change from baseline to Day 1 at 1 hour (h)-1.6 (-4.4 to 1.2)
Time-matched change from baseline to Day 1 at 2 h-3.1 (-6.0 to -0.3)
Time-matched change from baseline to Day 1 at 3 h-2.6 (-5.5 to 0.2)
Time-matched change from baseline to Day 1 at 4 h-2.6 (-5.4 to 0.3)
Time-matched change from baseline to Day 1 at 5 h-1.4 (-4.3 to 1.4)
Time-matched change from baseline to Day 1 at 6 h-2.0 (-4.8 to 0.9)
Time-matched change from baseline to Day 1 at 7 h-1.5 (-4.4 to 1.3)
Time-matched change from baseline to Day 1 at 10 h-3.6 (-6.4 to -0.7)
Time-matched change from baseline to Day 1 at 12 h-2.2 (-5.0 to 0.7)
SecondaryTime-matched Change From Baseline in QTcF Interval (QT Interval Corrected by the Fridericia Formula) at the Time of Each Participant's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Mean · milliseconds (ms)
Time-matched Change From Baseline in QTcF Interval (QT Interval Corrected by the Fridericia Formula) at the Time of Each Participant's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
milliseconds (ms)Nintedanib (BIBF 1120)
Time-matched change from baseline in QTcF interval at maximum BIBF 1120 concentration on Day 1-2.8 (-5.0 to -0.6)
Time-matched change from baseline in QTcF interval at maximum BIBF 1120 concentration on Day 15-3.2 (-5.9 to -0.4)
SecondaryTime-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Mean · milliseconds (ms)
Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
milliseconds (ms)Nintedanib (BIBF 1120)
Time-matched change from baseline in QTcF interval at maximum BIBF 1202 concentration on Day 1-2.5 (-4.6 to -0.5)
Time-matched change from baseline in QTcF interval at maximum BIBF 1202 concentration on Day 15-1.1 (-3.8 to 1.6)
SecondaryTime-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Mean · milliseconds (ms)
Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
milliseconds (ms)Nintedanib (BIBF 1120)
Time-matched change in QTcF from baseline at maximum BIBF 1202-glucuronide concentration on Day 1-2.4 (-4.9 to 0.0)
Time-matched change in QTcF from baseline at maximum BIBF 1202-glucuronide concentration on Day 15-1.5 (-4.2 to 1.2)
SecondaryAverage Time-matched Changes From Baseline in QTcF Interval Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1

Average time-matched in QTcF interval (QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula) changes over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

Time frame:
At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Reported as:
Mean · milliseconds (ms)
Average Time-matched Changes From Baseline in QTcF Interval Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1
milliseconds (ms)Nintedanib (BIBF 1120)
Averaged time-matched changes from baseline in QTcF interval over 1 h to 12 h after dosing on Day 1-2.2 (-3.5 to -0.8)
Averaged time-matched changes from baseline in QTcF interval over 1 h to 12 h after dosing on Day 150.5 (-1.4 to 2.3)
SecondaryTime-matched Changes From Baseline to Day 15 in QT Interval at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QT measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of Cycle 1are reported.

Time frame:
At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Reported as:
Least squares mean · milliseconds (ms)
Time-matched Changes From Baseline to Day 15 in QT Interval at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
milliseconds (ms)Nintedanib (BIBF 1120)
Time-matched QT interval change from baseline to Day 15 at -5 minutes (min)1.0 (-3.6 to 5.6)
Time-matched QT interval change from baseline to Day 15 at 1 hour (h)0.5 (-4.1 to 5.1)
Time-matched QT interval change from baseline to Day 15 at 2 h1.6 (-3.0 to 6.2)
Time-matched QT interval change from baseline to Day 15 at 3 h4.4 (-0.2 to 9.0)
Time-matched QT interval change from baseline to Day 15 at 4 h4.7 (0.0 to 9.3)
Time-matched QT interval change from baseline to Day 15 at 5 h5.1 (0.5 to 9.7)
Time-matched QT interval change from baseline to Day 15 at 6 h7.7 (3.1 to 12.3)
Time-matched QT interval change from baseline to Day 15 at 7 h7.1 (2.5 to 11.7)
Time-matched QT interval change from baseline to Day 15 at 10 h3.4 (-1.2 to 8.0)
Time-matched QT interval change from baseline to Day 15 at 12 h4.2 (-0.4 to 8.8)
SecondaryTime-matched Changes From Baseline to Day 1 in QT Interval at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QT measurement at time t. Time-matched change from baseline to Day 1 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported.

Time frame:
At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Reported as:
Least squares mean · millisecond (ms)
Time-matched Changes From Baseline to Day 1 in QT Interval at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
millisecond (ms)Nintedanib (BIBF 1120)
Time-matched QT interval change from baseline to Day 1 at 1 hour (h)-2.0 (-6.3 to 2.3)
Time-matched QT interval change from baseline to Day 1 at 2 h1.6 (-2.8 to 5.9)
Time-matched QT interval change from baseline to Day 1 at 3 h3.5 (-0.8 to 7.8)
Time-matched QT interval change from baseline to Day 1 at 4 h1.4 (-2.9 to 5.7)
Time-matched QT interval change from baseline to Day 1 at 5 h1.4 (-2.9 to 5.7)
Time-matched QT interval change from baseline to Day 1 at 6 h1.8 (-2.6 to 6.1)
Time-matched QT interval change from baseline to Day 1 at 7 h0.7 (-3.6 to 5.0)
Time-matched QT interval change from baseline to Day 1 at 10 h-1.7 (-6.0 to 2.7)
Time-matched QT interval change from baseline to Day 1 at 12 h-2.2 (-6.5 to 2.2)
SecondaryTime-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Mean · millisecond (ms)
Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
millisecond (ms)Nintedanib (BIBF 1120)
Time-matched change from baseline in QT interval at maximum BIBF 1120 concentration on Day 10.9 (-2.3 to 4.0)
Time-matched change from baseline in QT interval at maximum BIBF 1120 concentration on Day 15-0.4 (-5.0 to 4.1)
SecondaryTime-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Reported as:
Mean · millisecond (ms)
Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
millisecond (ms)Nintedanib (BIBF 1120)
Time-matched change from baseline in QT interval at maximum BIBF 1202 concentration on Day 11.2 (-1.9 to 4.3)
Time-matched change from baseline in QT interval at maximum BIBF 1202 concentration on Day 151.8 (-2.7 to 6.3)
SecondaryTime-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Mean · millisecond (ms)
Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
millisecond (ms)Nintedanib (BIBF 1120)
Time-matched change from baseline in QT at maximum BIBF 1202-glucuronide concentration on Day 1-0.4 (-4.0 to 3.1)
Time-matched change from baseline in QT at maximum BIBF 1202-glucuronide concentration on Day 151.3 (-3.2 to 5.9)
SecondaryAveraged Time-matched Changes From Baseline in QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1

Averaged time-matched QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

Time frame:
At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle.
Reported as:
Mean · millisecond (ms)
Averaged Time-matched Changes From Baseline in QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1
millisecond (ms)Nintedanib (BIBF 1120)
Averaged time-matched changes from baseline in QT interval over 1 h to 12 h after dosing on Day 10.9 (-1.3 to 3.0)
Averaged time-matched changes from baseline in QT interval over 1 h to 12 h after dosing on Day 154.2 (0.6 to 7.7)
SecondaryTime-Matched Heart Rate (HR) Changes From Baseline to Day 15 at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 15 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 15 obtained at time t minus baseline HR measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 15 of Cycle 1 are reported.

Time frame:
At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Reported as:
Least squares mean · beats per minute (bpm)
Time-Matched Heart Rate (HR) Changes From Baseline to Day 15 at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
beats per minute (bpm)Nintedanib (BIBF 1120)
Time-matched heart rate (HR) change from baseline to Day 15 at -5 minutes (min)0.9 (-1.2 to 3.0)
Time-matched heart rate (HR) change from baseline to Day 15 at 1 h-0.3 (-2.4 to 1.9)
Time-matched heart rate (HR) change from baseline to Day 15 at 2 h-2.0 (-4.2 to 0.1)
Time-matched heart rate (HR) change from baseline to Day 15 at 3 h-3.3 (-5.4 to -1.2)
Time-matched heart rate (HR) change from baseline to Day 15 at 4 h-3.4 (-5.5 to -1.3)
Time-matched heart rate (HR) change from baseline to Day 15 at 5 h-3.1 (-5.2 to -1.0)
Time-matched heart rate (HR) change from baseline to Day 15 at 6 h-3.8 (-5.9 to -1.7)
Time-matched heart rate (HR) change from baseline to Day 15 at 7 h-2.8 (-4.9 to -0.7)
Time-matched heart rate (HR) change from baseline to Day 15 at 10 h-2.4 (-4.5 to -0.5)
Time-matched heart rate (HR) change from baseline to Day 15 at 12 h-1.6 (-3.8 to 0.5)
SecondaryTime-Matched Heart Rate (HR) Changes From Baseline to Day 1 at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 1 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 1 obtained at time t minus baseline HR measurement at time t. Time-matched change from baseline to Day 1 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 1 are reported.

Time frame:
At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Reported as:
Least squares mean · beats per minute (bpm)
Time-Matched Heart Rate (HR) Changes From Baseline to Day 1 at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
beats per minute (bpm)Nintedanib (BIBF 1120)
Time-matched heart rate (HR) change from baseline to Day 1 at 1 hour (h)-0.0 (-1.9 to 1.8)
Time-matched heart rate (HR) change from baseline to Day 1 at 2 h-2.9 (-4.7 to -1.0)
Time-matched heart rate (HR) change from baseline to Day 1 at 3 h-3.8 (-5.7 to -2.0)
Time-matched heart rate (HR) change from baseline to Day 1 at 4 h-2.5 (-4.3 to -0.6)
Time-matched heart rate (HR) change from baseline to Day 1 at 5 h-1.8 (-3.7 to 0.0)
Time-matched heart rate (HR) change from baseline to Day 1 at 6 h-2.2 (-4.1 to -0.4)
Time-matched heart rate (HR) change from baseline to Day 1 at 7 h-1.4 (-3.3 to 0.4)
Time-matched heart rate (HR) change from baseline to Day 1 at 10 h-1.3 (-3.2 to 0.6)
Time-matched heart rate (HR) change from baseline to Day 1 at 12 h0.0 (-1.8 to 1.9)
SecondaryTime-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Nintedanib (BIBF 1120) Plasma Concentration, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Mean · beats per minute (bpm)
Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Nintedanib (BIBF 1120) Plasma Concentration, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
beats per minute (bpm)Nintedanib (BIBF 1120)
Time-matched change from baseline in HR at maximum BIBF 1120 concentration on Day 1-2.0 (-3.4 to -0.7)
Time-matched change from baseline in HR at maximum BIBF 1120 concentration on Day 15-2.1 (-4.3 to 0.1)
SecondaryTime-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Mean · beats per minute (bpm)
Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
beats per minute (bpm)Nintedanib (BIBF 1120)
Time-matched change from baseline in HR at maximum BIBF 1202 concentration on Day 1-2.3 (-3.8 to -0.8)
Time-matched change from baseline in HR at maximum BIBF 1202 concentration on Day 15-2.0 (-4.2 to 0.1)
SecondaryTime-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of treatment cycle 1. Continues in the description.
Reported as:
Mean · beats per minute (bpm)
Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
beats per minute (bpm)Nintedanib (BIBF 1120)
Time-matched change from baseline in HR at maximum BIBF 1202-glucuronide concentration on Day 1-1.2 (-2.6 to 0.3)
Time-matched change from baseline in HR at maximum BIBF 1202-glucuronide concentration on Day 15-1.6 (-3.6 to 0.4)
SecondaryAveraged Time-Matched Heart Rate (HR) Change From Baseline Over 1 to 12 Hours, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

Averaged time-matched heart rate changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.

Time frame:
At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15.
Reported as:
Mean · beats per minute (bpm)
Averaged Time-Matched Heart Rate (HR) Change From Baseline Over 1 to 12 Hours, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
beats per minute (bpm)Nintedanib (BIBF 1120)
Averaged time-matched HR change from baseline over 1 to 12 hours on Day 1-1.9 (-2.8 to -1.1)
Averaged time-matched HR change from baseline over 1 to 12 hours on Day 15-2.5 (-4.0 to -0.9)
SecondaryFrequency of Patients With Maximum Time-Matched QTcF Interval Change From Baseline Categorized by Magnitude of Change, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of patients with maximum time-matched change from baseline in the QTcF interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined: \<= 30 milliseconds (ms) \> 30 to 60 milliseconds (ms) \> 60 milliseconds (ms) Changes more than 60 ms in the QTcF interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Count of participants · Participants
Frequency of Patients With Maximum Time-Matched QTcF Interval Change From Baseline Categorized by Magnitude of Change, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
ParticipantsNintedanib (BIBF 1120)
Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hours (h) — <= 30 milliseconds (ms)64
Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hours (h) — > 30 to 60 milliseconds (ms)0
Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hours (h) — > 60 milliseconds (ms)0
Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — <= 30 milliseconds (ms)57
Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — > 30 to 60 milliseconds (ms)6
Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — > 60 milliseconds (ms)0
SecondaryFrequency of Patients With Maximum Time-Matched QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Change From Baseline Categorized by Magnitude of Change, Days 1 and 15

Number of patients with maximum time-matched change from baseline in the QT interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined: \<= 30 milliseconds (ms) \> 30 to 60 milliseconds (ms) \> 60 milliseconds (ms) Changes more than 60 ms in the QT interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Count of participants · Participants
Frequency of Patients With Maximum Time-Matched QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Change From Baseline Categorized by Magnitude of Change, Days 1 and 15
ParticipantsNintedanib (BIBF 1120)
Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hour (h) — <= 60 milliseconds (ms)64
Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hour (h) — > 60 milliseconds (ms)0
Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — <= 60 milliseconds (ms)62
Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — > 60 milliseconds (ms)1
SecondaryNumber of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF ≤450 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset (not present at any time pre-dose) of QTcF ≤450 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Count of participants · Participants
Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF ≤450 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
ParticipantsNintedanib (BIBF 1120)
Number of participants with new onset of QTcF ≤450 (ms) on Day 13
Number of participants with new onset of QTcF ≤450 (ms) on Day 152
SecondaryNumber of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF >450 to 470 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF \>450 to 470 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Reported as:
Count of participants · Participants
Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF >450 to 470 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
ParticipantsNintedanib (BIBF 1120)
Number of participants with new onset of QTcF >450 to 470 ms on Day 11
Number of participants with new onset of QTcF >450 to 470 ms on Day 151
SecondaryNumber of Participants With New Onset of QTcF> 470 to 500 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF\> 470 to 500 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Reported as:
Count of participants · Participants
Number of Participants With New Onset of QTcF> 470 to 500 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
ParticipantsNintedanib (BIBF 1120)
Number of participants with new onset of QTcF> 470 to 500 ms on Day 10
Number of participants with new onset of QTcF> 470 to 500 ms on Day 151
SecondaryNumber of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF> 500 Milliseconds (ms) (Notable Prolongation), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF\> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Reported as:
Count of participants · Participants
Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF> 500 Milliseconds (ms) (Notable Prolongation), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
ParticipantsNintedanib (BIBF 1120)
Number of participants with new onset of QTcF> 500 (ms) on Day 1, 1-12 hour (h)0
Number of participants with new onset of QTcF> 500 (ms) (notable prolongation) on Day 15, -0:05-12 h0
SecondaryNumber of Participants With New (Not Present at Any Time Pre-dose) Onset of QT (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) > 500 ms (Notable Prolongation), Days 1 and 15 of Treatment Cycle 1

Number of participants with new onset of QT (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave)\> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Reported as:
Count of participants · Participants
Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QT (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) > 500 ms (Notable Prolongation), Days 1 and 15 of Treatment Cycle 1
ParticipantsNintedanib (BIBF 1120)
Number of participants with new onset of QT> 500 (ms) on Day 1, 1-12 hour (h)0
Number of participants with new onset of QT> 500 (ms) on Day 15, -0:05-12 h0
SecondaryAbsolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in PR Interval

The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib) and at Day 1 (first drug dose of nintedanib (BIBF 1120)) and changes from baseline to Day 1 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported.

Time frame:
At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Reported as:
Mean · milliseconds (ms)
Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in PR Interval
milliseconds (ms)Nintedanib (BIBF 1120)
Absolute value in PR interval on Day -1 at -5 minutes (min)164.7 ± 23.8
Absolute value in PR interval on Day -1 at 1 hour (h)165.7 ± 24.9
Absolute value in PR interval on Day -1 at 2 h166.8 ± 24.9
Absolute value in PR interval on Day -1 at 3 h166.6 ± 24.0
Absolute value in PR interval on Day -1 at 4 h168.1 ± 26.9
Absolute value in PR interval on Day -1 at 5 h167.2 ± 26.3
Absolute value in PR interval on Day -1 at 6 h168.1 ± 26.4
Absolute value in PR interval on Day -1 at 7 h168.9 ± 27.5
Absolute value in PR interval on Day -1 at 10 h168.0 ± 26.7
Absolute value in PR interval on Day -1 at 12 h170.0 ± 29.4
Absolute value in PR interval on Day 1 at -5 min165.7 ± 25.6
Absolute value in PR interval on Day 1 at 1 h167.4 ± 28.2
Absolute value in PR interval on Day 1 at 2 h169.4 ± 28.2
Absolute value in PR interval on Day 1 at 3 h170.0 ± 27.3
Absolute value in PR interval on Day 1 at 4 h170.0 ± 28.2
Absolute value in PR interval on Day 1 at 5 h169.4 ± 27.5
Absolute value in PR interval on Day 1 at 6 h170.8 ± 27.9
Absolute value in PR interval on Day 1 at 7 h169.9 ± 27.0
Absolute value n PR interval on Day 1 at 10 h169.8 ± 26.3
Absolute value in PR interval on Day 1 at 12 h171.3 ± 28.7
Time-matched change from Day -1 to Day 1 in PR interval at -5 min0.7 ± 7.6
Time-matched change from Day -1 to Day 1 in PR interval at 1 h1.7 ± 11.6
Time-matched change from Day -1 to Day 1 in PR interval at 2 h2.6 ± 10.3
Time-matched change from Day -1 to Day 1 in PR interval at 3 h3.4 ± 9.1
Time-matched change from Day -1 to Day 1 in PR interval at 4 h2.2 ± 9.1
Time-matched change from Day -1 to Day 1 in PR interval at 5 h2.8 ± 10.7
Time-matched change from Day -1 to Day 1 in PR interval at 6 h3.3 ± 9.8
Time-matched change from Day -1 to Day 1 in PR interval at 7 h1.6 ± 9.3
Time-matched change from Day -1 to Day 1 in PR interval at 10 h1.8 ± 8.6
Time-matched change from Day -1 to Day 1 in PR interval at 12 h0.7 ± 9.4
SecondaryAbsolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in PR Interval

The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib (BIBF 1120) and at Day 15 (steady state) and changes from baseline to Day 15 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported.

Time frame:
At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Reported as:
Mean · milliseconds (ms)
Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in PR Interval
milliseconds (ms)Nintedanib (BIBF 1120)
Absolute value in PR interval on Day -1 at -5 minutes (min)164.7 ± 24.0
Absolute value in PR interval on Day -1 at 1 h165.7 ± 25.1
Absolute value in PR interval on Day -1 at 2 h166.8 ± 25.1
Absolute value in PR interval on Day -1 at 3 h166.5 ± 24.2
Absolute value in PR interval on Day -1 at 4 h168.0 ± 27.2
Absolute value in PR interval on Day -1 at 5 h167.2 ± 26.5
Absolute value in PR interval on Day -1 at 6 h168.3 ± 26.6
Absolute value in PR interval on Day -1 at 7 h168.9 ± 27.7
Absolute value in PR interval on Day -1 at 10 h168.1 ± 26.9
Absolute value in PR interval on Day -1 at 12 h170.1 ± 29.7
Absolute value in PR interval on Day 15 at -5 min164.5 ± 24.4
Absolute value in PR interval on Day 15 at 1 h166.1 ± 25.3
Absolute value in PR interval on Day 15 at 2 h166.8 ± 26.2
Absolute value in PR interval on Day 15 at 3 h167.4 ± 25.3
Absolute value in PR interval on Day 15 at 4 h168.7 ± 27.4
Absolute value in PR interval on Day 15 at 5 h167.7 ± 27.8
Absolute value in PR interval on Day 15at 6 h169.3 ± 26.7
Absolute value in PR interval on Day 15 at 7 h169.0 ± 27.9
Absolute value in PR interval on Day 15 at 10 h169.1 ± 27.9
Absolute value in PR interval on Day 15 at 12:00 h:min168.8 ± 27.9
Time-matched change from Day -1 to Day 15 in PR interval at -5 min-0.1 ± 10.6
Time-matched change from Day -1 to Day 15 in PR interval at 1 h0.5 ± 12.5
Time-matched change from Day -1 to Day 15 in PR interval at 2 h-0.0 ± 12.7
Time-matched change from Day -1 to Day 15 in PR interval at 3 h0.9 ± 14.6
Time matched - change from Day -1 to Day 15 in PR interval at 4 h0.9 ± 12.2
Time-matched change from Day -1 to Day 15 in PR interval at 5 h0.9 ± 13.7
Time-matched change from Day -1 to Day 15 in PR interval at 6 h1.3 ± 11.8
Time-matched change from Day -1 to Day 15 in PR interval at 7 h0.6 ± 13.2
Time-matched change from Day -1 to Day 15 in PR interval at 10 h1.2 ± 11.2
Time-matched change from Day -1 to Day 15 in PR interval at 12 h-1.5 ± 12.5
SecondaryAbsolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in QRS Interval

QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 1 (first drug dose of nintedanib (BIBF 1120)) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported.

Time frame:
At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Reported as:
Mean · milliseconds (ms)
Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in QRS Interval
milliseconds (ms)Nintedanib (BIBF 1120)
Absolute value in QRS interval on Day -1 at -5 minutes (min)92.4 ± 11.8
Absolute value in QRS interval on Day -1 at 1 h93.7 ± 11.0
Absolute value in QRS interval on Day -1 at 2 h93.2 ± 10.5
Absolute value in QRS interval on Day -1 at 3 h93.6 ± 10.8
Absolute value in QRS interval on Day -1 at 4 h92.7 ± 9.8
Absolute value in QRS interval on Day -1 at 5 h92.6 ± 11.0
Absolute value in QRS interval on Day -1 at 6 h92.5 ± 10.3
Absolute value in QRS interval on Day -1 at 7 h93.0 ± 10.6
Absolute value in QRS interval on Day -1 at 10 h92.8 ± 11.7
Absolute value in QRS interval on Day -1, 12 h92.5 ± 10.4
Absolute value in QRS interval on Day 1 at -5 min92.6 ± 10.1
Absolute value in QRS interval on Day 1 at 1 h93.2 ± 11.0
Absolute value in QRS interval on Day 1 at 2 h93.0 ± 10.4
Absolute value in QRS interval on Day 1 at 3 h93.3 ± 10.3
Absolute value in QRS interval on Day 1 at 4 h93.5 ± 11.1
Absolute value in QRS interval on Day 1 at 5 h93.4 ± 11.5
Absolute value in QRS interval on Day 1 at 6 h93.4 ± 10.7
Absolute value in QRS interval on Day 1 at 7 h93.2 ± 11.3
Absolute value in QRS interval on Day 1 at 10 h92.3 ± 10.6
Absolute value in QRS interval on Day 1 at 12 h92.8 ± 10.9
Time-matched change from Day -1 to Day 1 in QRS interval at -5 min0.7 ± 5.1
Time-matched change from Day -1 to Day 1 in QRS interval at 1 h-0.5 ± 5.2
Time-matched change from Day -1 to Day 1 in QRS interval 2 h-0.2 ± 4.4
Time-matched change from Day -1 to Day 1 in QRS interval at 3h-0.3 ± 4.4
Time-matched change from Day -1 to day 1 in QRS interval at 4 h0.2 ± 4.7
Time-matched change from Day -1 to Day 1 in QRS interval at 5 h0.2 ± 5.4
Time-matched change from Day -1 to Day 1 in QRS interval at 6 h0.3 ± 5.6
Time-matched change from Day -1 to Day 1 in QRS interval at 7 h-0.2 ± 4.7
Time-matched change from Day -1 to Day 1 in QRS interval at 10 h-0.5 ± 4.9
Time-matched change from Day -1 to Day 1 in QRS interval at 12 h0.3 ± 4.9
SecondaryAbsolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in QRS Interval

QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 15 (steady state) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported.

Time frame:
At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Reported as:
Mean · milliseconds (ms)
Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in QRS Interval
milliseconds (ms)Nintedanib (BIBF 1120)
Absolute value in QRS interval on Day -1 at -5 minutes (min)92.5 ± 11.8
Absolute value in QRS interval on Day -1 at 1 hour (h)93.8 ± 11.1
Absolute value in QRS interval on Day -1 at 2 h93.3 ± 10.6
Absolute value in QRS interval on Day -1 at 3 h93.6 ± 10.9
Absolute value in QRS interval on Day -1 at 4 h92.7 ± 9.9
Absolute value in QRS interval on Day -1 at 5 h92.7 ± 11.0
Absolute value in QRS interval on Day -1 at 6 h92.7 ± 10.3
Absolute value in QRS interval on Day -1 at 7 h93.1 ± 10.6
Absolute value in QRS interval on Day -1 at 10 h92.8 ± 11.8
Absolute value in QRS interval on Day -1 at 12 h92.6 ± 10.4
Absolute value in QRS interval on Day 15 at -5 min93.3 ± 11.0
Absolute value Day 15, 1 h93.9 ± 10.3
Absolute value in QRS interval on Day 15 at 2 h93.0 ± 11.5
Absolute value in QRS interval on Day 15 at 3 h92.9 ± 11.1
Absolute value in QRS interval on Day 15 at 4 h92.6 ± 11.2
Absolute value in QRS interval on Day 15 at 5 h93.6 ± 10.9
Absolute value in QRS interval on Day 15 at 6 h93.1 ± 11.1
Absolute value in QRS interval on Day 15 at 7 h93.1 ± 11.3
Absolute value in QRS interval on Day 15 at 10 h92.8 ± 10.7
Absolute value in QRS interval on Day 15 at 12 h93.7 ± 11.5
Time-matched change from Day -1 to Day 15 in QRS interval at -5 min0.8 ± 5.4
Time-matched change from Day -1 to Day 15 in QRS interval at 1 h0.0 ± 5.1
Time-matched change from Day -1 to Day 15 in QRS interval at 2 h-0.3 ± 5.3
Time-matched change from Day -1 to Day 15 in QRS interval at 3 h-0.8 ± 5.7
Time-matched change from Day -1 to Day 15 in QRS interval at 4 h-0.6 ± 5.4
Time-matched change from Day -1 to Day 15 in QRS interval at 5 h0.5 ± 7.3
Time-matched change from Day -1 to Day 15 in QRS interval at 6 h-0.1 ± 5.3
Time-matched change from Day -1 to Day 15 in QRS interval at 7 h-0.4 ± 5.3
Time-matched change from Day -1 to Day 15 in QRS interval at 10 h0.1 ± 5.1
Time-matched change from Day -1 to Day 15 in QRS interval at 12 h1.0 ± 4.7
SecondaryFrequency of Patients by Clinical Electrocardiogram (ECG) Measurement Interpretation, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

Based on the interpretation of the electrocardiogram (ECG) patients were classified in 3 categories: * Normal (a normal ECG reading would be a reading that includes the following normal findings: 1) normal general features; 2) no arrhythmia; 3) no conduction delays; 4) T-wave morphology of normal; and 5) normal U-wave morphology) on Day 1 or on Day 15) * Not normal and not normal at baseline (an abnormal ECG reading would be a reading that includes one or more of the following abnormal findings: 1) abnormal general features; 2) arrhythmia; 3) conduction delays; 4) T-wave morphology of flat, inverted or biphasic; and 5) abnormal U-wave morphology) on Day 1 or on Day 15) * Not normal and new onset of finding; Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Time frame:
At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Reported as:
Count of participants · Participants
Frequency of Patients by Clinical Electrocardiogram (ECG) Measurement Interpretation, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
ParticipantsNintedanib (BIBF 1120)
ECG interpretation on Day 1 — Normal39
ECG interpretation on Day 1 — Not normal and not normal at baseline24
ECG interpretation on Day 1 — Not normal and new onset of finding1
ECG interpretation on Day 15 — Normal37
ECG interpretation on Day 15 — Not normal and not normal at baseline25
ECG interpretation on Day 15 — Not normal and new onset of finding1
SecondaryFrequency of Adverse Events Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0

The number of participants who experienced adverse events graded according to NCI CTCAE version 3.0, is reported below.The maximum grade of adverse event intensity for each type of treatment-related adverse event was recorded for each patient. Grade 1 - Mild AE Grade 2 - Moderate AE Grade 3 - Severe AE Grade 4 - Life-threatening or disabling AE Grade 5 - Death related to AE

Time frame:
From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Reported as:
Count of participants · Participants
Frequency of Adverse Events Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0
ParticipantsNintedanib (BIBF 1120)Sunitinib
Grade 1115
Grade 2166
Grade 31416
Grade 4102
Grade 571
SecondaryNumber of Participants With Adverse Events Leading to Dose Reduction

Number of participants who experienced Adverse Events which led to dose reduction of the trial medication is reported for each treatment arm.

Time frame:
From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Dose Reduction
ParticipantsNintedanib (BIBF 1120)Sunitinib
Number of Participants With Adverse Events Leading to Dose Reduction168
SecondaryNumber of Participants With Adverse Events Leading to Discontinuation of Trial Drug

Number of participants with Adverse Events which lead to discontinuation of trial medication drug is reported for each treatment arm.

Time frame:
From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Discontinuation of Trial Drug
ParticipantsNintedanib (BIBF 1120)Sunitinib
Number of Participants With Adverse Events Leading to Discontinuation of Trial Drug115
SecondaryNumber of Participants With Adverse Events Requiring or Prolonging Hospitalisation

Number of participants who experienced Adverse Events which required or prolonged hospitalisation of patients is reported for each treatment arm.

Time frame:
From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Requiring or Prolonging Hospitalisation
ParticipantsNintedanib (BIBF 1120)Sunitinib
Number of Participants With Adverse Events Requiring or Prolonging Hospitalisation1510
SecondaryDuration of Hospital Stays Due to Adverse Events Requiring or Prolonging Hospitalisation

Duration of hospitalisation in days for each treatment arm is reported for those patients who experienced adverse events which required or prolonged hospitalisation (of the patients).

Time frame:
From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Reported as:
Mean · days
Duration of Hospital Stays Due to Adverse Events Requiring or Prolonging Hospitalisation
daysNintedanib (BIBF 1120)Sunitinib
Duration of Hospital Stays Due to Adverse Events Requiring or Prolonging Hospitalisation11.40 ± 8.5613.10 ± 8.32
SecondaryFrequency of Patients With Possible Clinically Significant Abnormal Lab Values

Number of patients with possible clinically significant abnormal lab values for the lab parameters alkaline phosphatase, activated partial thromboplastin time (APTT), creatinine, haemoglobin, prothrombin time (PT)-international normalized ratio (INR), potassium, lymphocytes, sodium, neutrophils, platelets, aspartate amino transferase (AST), alanine aminotransferase (ALT), bilirubin and white blood cell count is reported. Only lab values with CTCAE rule for possible clinical significance are displayed.

Time frame:
From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Reported as:
Count of participants · Participants
Frequency of Patients With Possible Clinically Significant Abnormal Lab Values
ParticipantsNintedanib (BIBF 1120)Sunitinib
Alkaline phosphatase23
APTT (Activated partial thrombopl. time)70
Creatinine45
Haemoglobin66
Prothrombin time (PT)-international normalized ratio (INR)50
Potassium144
Lymphocytes811
Sodium143
Neutrophils39
Platelets23
Aspartate amino Transferase (AST)101
Alanine aminotransferase (ALT)143
Bilirubin, total43
White blood cell count07

Adverse events

Collected over From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib (BIBF 1120)50/64 (78.1%)20/64 (31.3%)55/64 (85.9%)
Sunitinib25/32 (78.1%)11/32 (34.4%)27/32 (84.4%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventNintedanib (BIBF 1120)Sunitinib
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/640/32
NauseaGastrointestinal disorders0/643/32
Abdominal painGastrointestinal disorders0/642/32
Myocardial infarctionCardiac disorders1/641/32
Abdominal pain upperGastrointestinal disorders0/641/32
AscitesGastrointestinal disorders0/641/32
DiarrhoeaGastrointestinal disorders0/641/32
Gastrointestinal haemorrhageGastrointestinal disorders0/641/32
VomitingGastrointestinal disorders0/641/32
Disease progressionGeneral disorders0/641/32
Most frequent other events
Showing 10 of 52
Most frequent other events
EventNintedanib (BIBF 1120)Sunitinib
DiarrhoeaGastrointestinal disorders40/6415/32
NauseaGastrointestinal disorders25/648/32
StomatitisGastrointestinal disorders0/6410/32
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/6410/32
FatigueGeneral disorders17/648/32
DyspepsiaGastrointestinal disorders3/647/32
VomitingGastrointestinal disorders10/646/32
Decreased appetiteMetabolism and nutrition disorders12/646/32
AnaemiaBlood and lymphatic system disorders4/645/32
HypothyroidismEndocrine disorders2/645/32

Baseline characteristics

Treated set: all patients who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.

Age, Continuous
Age, Continuous(Years)Nintedanib (BIBF 1120)SunitinibTotal
Mean60.4 ± 9.755.5 ± 11.458.8 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Nintedanib (BIBF 1120)SunitinibTotal
Female201030
Male442266
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nintedanib (BIBF 1120)SunitinibTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White643296
More than one race000
Unknown or Not Reported000
QTcF interval baseline values
QTcF interval baseline values(millisecconds (ms))Nintedanib (BIBF 1120)SunitinibTotal
-5 minutes405.2 ± 19.6—405.2 ± 19.6
1 hour (h)406.0 ± 20.3—406.0 ± 20.3
2 h405.3 ± 19.4—405.3 ± 19.4
3 h406.7 ± 19.4—406.7 ± 19.4
4 h407.0 ± 17.8—407.0 ± 17.8
5 h407.2 ± 18.0—407.2 ± 18.0
6 h405.9 ± 18.3—405.9 ± 18.3
7 h405.4 ± 19.2—405.4 ± 19.2
10 h406.6 ± 19.2—406.6 ± 19.2
12 h406.0 ± 19.2—406.0 ± 19.2
08

Study locations

15 sites
  • University of Pecs Medical School, Dept. of Oncotherapy
    Pecs, 7624, Hungary
  • Ziemia Lubelska Oncological Center, Lublin
    Lublin, 20-099, Poland
  • Onco.Cent. - Instit. of Maria Sklodowskiej-Curie
    Warszawa, 02-781, Poland
  • Military Central Clinical Emergency Hospital
    Bucharest, 010825, Romania
  • Sf. Nectarie Oncology Center, Craiova
    Craiova, 200347, Romania
  • ONCOLAB SRL, Craiova
    Craiova, 200385, Romania
  • Municipal Establishment Cherkasy Oncology Centre
    Cherkasy, 18009, Ukraine
  • Bukovynsk State Medical University
    Chernivtsi, 58013, Ukraine
  • Munic.Instit."City Clin.Hosp.#4" of Dnipro City Council
    Dnipropetrovks, 49102, Ukraine
  • CI of LRC Lviv Onco.Reg.Treat.&Diag.Cent.
    Lviv, 79031, Ukraine
  • Uzhgorod National University, Oncology Centre
    Uzhgorod, 88000, Ukraine
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • Surrey Cancer Research Institute
    Guildford, GU2 7WG, United Kingdom
  • St James's University Hospital
    Leeds, LS9 7TF, United Kingdom
09

References and documents

Publications

  • Eisen T, Shparyk Y, Macleod N, Jones R, Wallenstein G, Temple G, Khder Y, Dallinger C, Studeny M, Loembe AB, Bondarenko I. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Invest New Drugs. 2013 Oct;31(5):1283-93. doi: 10.1007/s10637-013-9962-7. Epub 2013 Apr 27. PubMed 23625328 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Nov 2011 and a completion of Jun 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2020, 8 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2009
First posted
Dec 3, 2009
Start
Dec 16, 2009
Primary completionActual
Nov 8, 2011
CompletionActual
Jun 19, 2020
Results first posted
Jun 17, 2020
Last update
Jul 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01024920
Responsible party
Sponsor
First posted
Dec 3, 2009
Start date
Dec 16, 2009
Primary completion
Nov 8, 2011
Completion
Jun 19, 2020
Results posted
Jun 17, 2020
Last update
Jul 19, 2021

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion